Keros Q2 FY26 net loss narrows to $28.7 million; R&D expenses drop 48.74% to $22.3 million

Reuters2026/08/03 20:01

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Keros Therapeutics posted a Q2 net loss of USD 28.7 million, narrowing from a USD 30.7 million loss a year earlier.
Revenue was no revenue, versus USD 18.17 million a year earlier.
R&D expenses fell 48.74% to USD 22.3 million, due to shifting elritercept R&D to Takeda and a 2025 restructuring.
G&A costs dropped 40.69% to USD 8.6 million on lower professional fees and compensation tied to the restructuring.
Initiated a Phase 2 rinvatercept trial in Duchenne muscular dystrophy; initial data expected in H1 2027, cash runway seen into H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031601PRIMZONEFULLFEED9802617) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Keros Q2 FY26 net loss narrows to $28.7 million; R&D expenses drop 48.74% to $22.3 million

You may also like

Crypto prices